KR20170029828A - Antidiabetic composition comprising complex of wild soya bean and banaba leaves - Google Patents
Antidiabetic composition comprising complex of wild soya bean and banaba leaves Download PDFInfo
- Publication number
- KR20170029828A KR20170029828A KR1020150126903A KR20150126903A KR20170029828A KR 20170029828 A KR20170029828 A KR 20170029828A KR 1020150126903 A KR1020150126903 A KR 1020150126903A KR 20150126903 A KR20150126903 A KR 20150126903A KR 20170029828 A KR20170029828 A KR 20170029828A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- complex
- mixture
- leaf
- powder
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000003178 anti-diabetic effect Effects 0.000 title abstract description 10
- 244000068988 Glycine max Species 0.000 title abstract description 9
- 235000010469 Glycine max Nutrition 0.000 title abstract description 9
- 239000003472 antidiabetic agent Substances 0.000 title description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 3
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract 3
- 239000000284 extract Substances 0.000 claims description 56
- 239000000843 powder Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 244000102209 Crateva religiosa Species 0.000 claims description 19
- 235000003494 Crateva religiosa Nutrition 0.000 claims description 19
- 239000010459 dolomite Substances 0.000 claims description 18
- 229910000514 dolomite Inorganic materials 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 244000017020 Ipomoea batatas Species 0.000 claims description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 2
- 241000219315 Spinacia Species 0.000 claims 7
- 235000005881 Calendula officinalis Nutrition 0.000 claims 3
- 240000000785 Tagetes erecta Species 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 17
- 239000002131 composite material Substances 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 34
- 239000008280 blood Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 27
- 239000000469 ethanolic extract Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 229960001031 glucose Drugs 0.000 description 18
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 229940125396 insulin Drugs 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 5
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 244000058871 Echinochloa crus-galli Species 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000300264 Spinacia oleracea Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000010030 glucose lowering effect Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 235000013379 molasses Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000238586 Cirripedia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000219764 Dolichos Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101800004415 Glucagon-29 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241001300423 Strophostyles Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940089126 diabeta Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 229940088991 glucotrol Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Abstract
Description
본 발명은 항당뇨 조성물에 관한 것으로, 더욱 상세하게는 돌콩과 바나바잎 복합물을 주성분으로 하는 항당뇨 조성물에 관한 것이다.The present invention relates to an anti-diabetic composition, and more particularly, to an anti-diabetic composition comprising as an active ingredient a combination of a starch and a banaba leaf.
당뇨병(diabetes mellitus)은 인슐린 분비가 감소되거나 인슐린의 기능이 저하되어 체내의 세포가 당을 이용하지 못하여 고혈당이 발생하는 질환이다. 당뇨병의 경우, 인슐린을 비롯한 호르몬의 불균형으로 인하여 탄수화물, 단백질, 지질, 전해질 등 생리적 대사 조절 기능에 이상이 발생하여 고혈당의 특징적인 증세를 나타낸다. 이러한 고혈당 증세가 지속되면 혈액순환 장애, 망막손상, 신경세포 손상, 신장 기능 저하, 혈관 합병증 등을 유발하고 심각한 만성적 합병증을 가져오게 된다.Diabetes mellitus is a disorder in which insulin secretion is reduced or insulin function is lowered, resulting in hyperglycemia due to inability of cells in the body to utilize sugar. In the case of diabetes, abnormalities in the physiological metabolism control function such as carbohydrate, protein, lipid, and electrolyte are caused by the imbalance of the hormone including insulin, and the characteristic symptom of hyperglycemia is shown. If such hyperglycemia persists, it causes blood circulation disorder, retinal damage, nerve cell damage, kidney dysfunction, vascular complication, and causes serious chronic complications.
특히, 정상인에 비해서 당뇨환자에 있어서는 동맥경화증, 뇌경색, 뇌혈전, 심근경색과 같은 심혈관계 질환의 발병율이 높다(Fuller, J.H., Lancet, 1, pp1373-1376, 1980). 당뇨병환자는 관상동맥질환이나 뇌혈관질환에 의한 사망위험률이 높고, 이러한 질환들은 고혈압과 고지혈증, 비만 등에 의하여 흔히 발병된다(허갑범. 한국영양학회. 초록발표논문집. pp15-18, 1984). 제2형 당뇨환자 중 67%가 한 종류 또는 그 이상의 지질대사이상을 가지고 있는 것으로 보고되었다(Harris, M.I. Diabetes Care, 23, pp754-758, 2000). 제2형 당뇨환자는 중성지방 및 콜레스테롤 농도가 증가하고 HDL-콜레스테롤이 감소하는 지질대사의 이상이 일어나며(Goldberg, R.B. Diabetes Care, 4, pp561-572, 1981), 이는 당뇨합병증인 관상동맥질환의 원인이 된다(Reaven, J.W. Am. J. Med., 83, pp31-40, 1987).In particular, the incidence of cardiovascular diseases such as arteriosclerosis, cerebral infarction, cerebral thrombosis, and myocardial infarction is higher in diabetic patients than in normal subjects (Fuller, J.H., Lancet, 1, pp1373-1376, 1980). In diabetic patients, the risk of death from coronary artery disease or cerebrovascular disease is high, and these diseases are often caused by hypertension, hyperlipidemia, obesity, etc. (Korean Journal of Nutrition, pp15-18, 1984). 67% of type 2 diabetes patients were reported to have one or more lipid metabolism abnormalities (Harris, M.I. Diabetes Care, 23, pp754-758, 2000). In patients with type 2 diabetes, lipid metabolism abnormality occurs in which triglyceride and cholesterol levels increase and HDL-cholesterol decreases (Goldberg, RB Diabetes Care, 4, pp561-572, 1981), which suggests that diabetic complications such as coronary artery disease (Reaven, JW Am. J. Med., 83, pp 31-40, 1987).
당뇨병은 췌장세포에서 분비되는 인슐린의 분비장애 및 작용부족에 의해 유발된 대사장애로 정의되며, 포도당의 과잉생산, 체지방의 분해 및 단백질의 낭비를 수반하고 글루카곤의 분비를 비정상적으로 항진시켜 대사상의 혼란을 야기시킨다(Abrams, J.J., Ginsberg, H, et al., Diabetes, 31, pp903-910, 1982). Diabetes is defined as a metabolic disorder caused by insulin secretion and insufficient secretion from the pancreas cells. It is accompanied by overproduction of glucose, body fat breakdown, protein waste, abnormal hyperglycemia of glucagon, (Abrams, JJ, Ginsberg, H, et al., Diabetes, 31, pp 903-910, 1982).
진성당뇨병(Diabetes mellitus)에는 제1형 당뇨병과 제2형 당뇨병의 2가지 유형이 있다. 제1형 당뇨병(Type 1 diabetes mellitus)은 혈액 내의 포도당 조절 호르몬인 인슐린의 분비가 결핍되어 발생하며, 주로 10~20대의 젊은 연령층에서 발병되기 때문에 소아당뇨병(Juvenile diabetes)이라 불리기도 한다. 제2형 당뇨병(Type 2 diabetes mellitus)은 주로 40대 이후에 발병되며, 우리나라 당뇨병 환자의 대부분을 차지한다. 제2형 당뇨병은 성인형 당뇨병이라 불리며 발병원인은 아직 명확히 밝혀져 있지 않으나, 유전적인 요인과 환경적 요인이 함께 관여되어 발생하는 것으로 알려져 있다. 제2형 당뇨병의 병인으로는, 췌장 베타세포에서의 인슐린 분비장애와 표적세포에서의 인슐린 작용결함(인슐린 저항성)이 모두 관찰된다.There are two types of diabetes mellitus: type 1 diabetes and type 2 diabetes. Type 1 diabetes mellitus is caused by a deficiency of insulin secretion, a glucose-regulating hormone in the blood, and is often referred to as juvenile diabetes because it occurs in young people aged 10 to 20 years. Type 2 diabetes mellitus occurs mainly after the age of 40, and it accounts for most of the diabetic patients in Korea. Type 2 diabetes is called adult type diabetes and the cause of the disease is not clear yet, but genetic factors and environmental factors are known to occur together. In the pathogenesis of type 2 diabetes, both insulin secretory defects in pancreatic beta cells and insulin action defects in target cells (insulin resistance) are observed.
당뇨병 치료에 있어서 가장 중요한 목표는 혈당치를 가능한 정상치에 가깝게 조절하는 것인데, 공복혈당과 함께 식후혈당의 조절이 당뇨병 증세의 개선과 합병증의 예방 및 치료에 있어서 중요하다. 현재 사용되는 당뇨병의 치료방법으로는 약물요법, 식이요법 및 운동요법이 있다. The most important goal in the treatment of diabetes is to adjust the blood glucose level as close to normal as possible. Control of postprandial blood glucose with fasting blood glucose is important in the improvement of diabetic symptoms and prevention and treatment of complications. Current methods of treating diabetes include drug therapy, diet and exercise therapy.
현재 제1형 및 제2형 당뇨병환자에게 사용되는 경구혈당강하제로 α-글리코시다제(α-glucosidase) 억제제, 설포닐우레아(Sulfonylurea) 제제 및 비구아니드(Biguanide) 제제가 있다. α-글루코시다제 억제제는 섭취한 식이 중의 탄수화물의 소화와 흡수를 지연시켜 식후 혈당 및 혈중 인슐린의 상승을 감소시킴으로써 당뇨병의 치료효과를 나타내는데, 고인슐린혈증이나 저혈당을 유발하지 않고, 인슐린분비를 촉진시키며 글루카곤 분비를 억제하는 글루카곤-유사-펩티드-1(Glucagon-like peptide-1)의 소장에서의 분비를 촉진하는 장점을 가지고 있다(Mooradian, A.D., Thurman, J.E. et al., Drugs, 57, pp19-29, 1999; Baron, A.D. et al., Diabetes Research and Clinical Practice, 40, ppS54-S55, 1998). 그러나 α-글리코시다제 저해제를 장기복용하는 경우, 일부 환자에게서 복부 팽만감, 구토, 설사 등의 부작용이 생길 수 있어서 그 사용이 제한될 수 있다 (Hanefeld, M. et al., Journal of Diabetes and its Complications, 12, pp228-237, 1998). α-글루코시다제 억제제로 현재 임상에서 사용하고 있는 것으로는 아카보스(Acarbose), 보글리보스(Voglibose) 및 미글리톨(Miglitol) 등이 있다. 설포닐우레아 제제는 인체가 인슐린을 더 많이 배출하도록 하고, 인체가 인슐린에 반응하는 것을 도와주며, 간에 저장된 포도당을 혈액 속으로 내보내는 것을 막아주어 혈당을 낮춘다. 설포닐우레아 제제의 부작용으로는 변비, 설사, 구역, 구토 등의 위장관 장해, 가려움, 두드러기 등의 피부반응, 체중 증가 등이 보고되어 있다. 이 계열에 속하는 약으로는 글리메피리드(아마릴™), 글리피자이드(글루코트롤™), 글리부라이드(다이아베타™) 등이 있다. 비구아니드(Biguanide) 제제로는 메트포르민(글루코파지™)이 현재 시판되고 있는데, 비구아니드 제제는 간이 저장 포도당을 보다 서서히 방출시키도록 하면서 인체가 인슐린에 반응하는 것을 도와줌으로써 혈당을 보다 일정하게 유지시켜 준다. 비구아니드 제제의 부작용으로는 구역, 팽만감, 갑갑함, 설사, 식욕부진 등이 보고되어 있다. Currently, oral hypoglycemic agents used in patients with type 1 and type 2 diabetes include α-glucosidase inhibitors, sulfonylurea agents and biguanide agents. The α-glucosidase inhibitor shows the therapeutic effect of diabetes by reducing the postprandial blood glucose and blood insulin elevation by delaying the digestion and absorption of the carbohydrate in the ingested diet. It does not induce hyperinsulinemia or hypoglycemia and promotes insulin secretion (Mooradian, AD, Thurman, JE et al., Drugs, 57, pp19 (1995)), which has the advantage of promoting secretion in the small intestine of glucagon-like peptide-1 inhibiting the secretion of glucagon -29, 1999; Baron, AD et al., Diabetes Research and Clinical Practice, 40, ppS54-S55, 1998). However, long-term use of the α-glycosidase inhibitor may result in side effects such as abdominal bloating, vomiting, and diarrhea in some patients, which may limit their use (Hanefeld, M. et al., Journal of Diabetes and its Complications, 12, pp228-237, 1998). Acarbose, Voglibose and Miglitol are currently used in clinical trials as α-glucosidase inhibitors. Sulphonylurea drugs help the body to release more insulin, help the body respond to insulin, and lower blood sugar by preventing the release of stored glucose into the blood. Side effects of sulfonylurea drugs include gastrointestinal disturbances such as constipation, diarrhea, nausea and vomiting, skin reactions such as itching, urticaria, and weight gain. Drugs belonging to this family include glimepiride (Amaryl ™), glypizide (Glucotrol ™), and glyburide (Diabeta ™). Metformin (Glucophage ™) is now on the market as a Biguanide agent, which allows the body to slowly release glucose from the liver and help the body respond to insulin, It keeps. Side effects of bingonide dejugation include zone, bloating, bumpiness, diarrhea and poor appetite.
돌콩(Wild soya bean, Glycine soja Sieb. et Zucc.)은 콩과 (Zingiberaceae)에 속하는 덩굴성 1년초로 길이는 2m이며 전체에 갈색의 거친 털이 나있다. 잎은 호생이고 잎자루는 길며 3출엽이다. 작은 잎은 타원상 피침형으로 끝이 둔하고 길이는 3-8cm이고 가장자리는 밋밋하며, 턱잎은 넓은 피침형이다. 꽃은 7~8월에 홍자색으로 피는데 총상꽃차례[總狀花序]는 길이 2~5cm이다. 꽃받침은 종형이고 털이 있으며 5개로 갈라지며, 화관은 나비모양이다. 수술은 10개로서 각각 2개로 갈라진다. 열매는 2~3cm로 털이 많고 콩꼬투리와 비슷하며, 종자는 타원형이거나 신장형 비슷하며 약간 편평하다(이영노. 원색한국식물도감, (주)교학사, 403p, 1998). 돌콩은 이명으로 갱미두, 녹곽으로 불리며, 생약명으로는 야대두등(野大豆藤), 야료두(野料豆)로 불리운다(안덕균, 한국본초도감, 교학사, 728p,2000). 돌콩은 콩(Glycine max)의 기원종으로 여겨지고 있으며, 현재 식용 가능한 것으로 인정되고 있으나 실제 식용으로 이용되는 경우는 거의 없으며, 대부분 자연계에서 자생하고 있고 강한 유전자를 지니고 있어 콩의 유전적 개량 연구 등을 위해 일부 재배되기도 한다. 돌콩 추출물은 우수한 항당뇨효과를 가지며, 돌콩 추출물의 항당뇨효과와 관련하여 본 발명자의 특허 제10-1400368호는 돌콩의 열처리 분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물에 대하여 개시하고 있다.Wild soybean, Glycine soja Sieb. et Zucc.) belongs to the zingiberaceae, 1-year-old, with a length of 2 m, with brownish rough hairs throughout. Leaves are hyphae, petioles are long and 3 leaflets. The small leaf is oval lanceolate, dull end, 3-8cm in length, flat on edge, and stipule is broad lanceolate. The flowers bloom in July to August in reddish purple color. The flower buds are 2 ~ 5cm long. Calyx is bell-shaped, has hairs, is divided into 5 pieces, and the corolla is butterfly-shaped. Surgery is divided into 10 pieces each. The fruit is 2 ~ 3cm long with many hairs, similar to the bean pods, and the seeds are oval or similar to the kidneys and are slightly flat (Lee Yongno, primary color Korea Botanical Illustrated Co., Ltd., 403p, 1998). It is called as ginkgo biloba and rustic bark, and it is called as soybean bean and wild bean bean as a generic name. (Ahn, Duk-Gyun, Korea Basic Book Illustrated, Dean, 728p, 2000). Dolch is considered to be the origin of soybean ( Glycine max ) and is recognized as possible edible now, but it is rarely used for practical use. Most of it is native in nature and has a strong gene. Some are cultivated for. The present invention relates to a method for the prevention and treatment of diabetes mellitus and diabetic complications, which comprises the heat-treated powder or extract of dolomoe as an active ingredient. ≪ / RTI >
바나바(Banaba, Lagerstroemmia speciosa Pers.)는 열대 아열대 지방에서 자생하는 다년생 상록수이며, 필리핀에서는 예부터 항당뇨병 약용식물로 사용해 왔다. 바나바잎의 주된 항당뇨성분은 코로솔산(Corosolic acid)으로, 코로솔산은 항당뇨에 직접적이기보다는 간접적인 관계에 있어 수용체에 부착하여 인슐린의 활성을 높이는 것으로 확인되었다. 그 외에 바나바에는 식물섬유도 많이 포함되어 있어 배변량을 증가시켜 변비예방, 비만예방, 콜레스테롤 저하작용, 대장암과 유해물질의 독성경감에도 관여하는 것으로 알려져 있다.Banaba (Lagerstroemmia speciosa Pers.) Is a perennial evergreen tree native to the tropical subtropics and has been used as an anti-diabetic medicinal plant in the Philippines for some time. The main antidiabetic component of banaba leaf was corosolic acid, and corosolic acid was found to indirectly bind to the receptor and enhance insulin activity, rather than directly to antidiabetic activity. In addition, there is a lot of vegetable fiber in barnabe, which increases the defecation to prevent constipation, prevention of obesity, cholesterol lowering action, is also known to be involved in the reduction of toxic and toxic substances in colon cancer.
본 발명은 돌콩과 바나바잎을 일정 비율로 혼합한 복합물을 구성하여, 부작용은 없으면서 혈당강하작용을 크게 높인, 당뇨병 예방과 치료 및 개선을 위한 새로운 약학 조성물 및 식품 조성물을 제공하고자 한다. The present invention provides a novel pharmaceutical composition and food composition for preventing, treating and improving diabetes mellitus, which comprises a complex of a mixture of a barnyard and a banaba leaf at a predetermined ratio, thereby greatly enhancing a blood glucose lowering effect without side effects.
상기 목적을 달성하기 위하여, 본 발명은 돌콩과 바나바잎 복합물을 유효성분으로 함유하는 당뇨병의 예방 및 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating diabetes mellitus containing as an active ingredient, a complex of stigma and banaba leaf.
상기 약학 조성물에서, 상기 복합물은 돌콩 추출물과 바나바잎 추출물의 혼합물; 돌콩분말과 바나바잎 추출물의 혼합물; 돌콩과 바나바잎의 혼합추출물 중 어느 하나 이상이 될 수 있다. In the above pharmaceutical composition, the complex may be a mixture of Dolomoe extract and Barnaby leaf extract; A mixture of dolchol powder and barnaby leaf extract; And a mixed extract of dolomite and barnaby leaf.
상기 돌콩 추출물과 바나바잎 추출물의 혼합물일 때, 상기 복합물은 돌콩과 바나바잎을 각각 0~100℃에서 물, 탄소수 1~4의 유기용매 또는 이들의 혼합용매로 추출하여 얻은 돌콩 추출물과 바나바잎 추출물을 일정 비율로 혼합한 것임이 바람직하다. 이때 돌콩 추출물과 바나바잎 추출물을 1:3 내지 3:1의 중량비로 혼합하는 것이 바람직하다. In the case of a mixture of the extract of Dolomoe and Baraba leaves, the complex is obtained by extracting a mixture of Dolk and Baraba leaves with water, an organic solvent having 1 to 4 carbon atoms or a mixed solvent thereof, at 0 to 100 ° C, Are mixed at a certain ratio. At this time, it is preferable to mix the barnyardgrass extract and the barna leaf extract at a weight ratio of 1: 3 to 3: 1.
상기 복합물이 돌콩과 바나바잎의 혼합물일 때, 상기 복합물은 돌콩과 바나바잎의 혼합물을 0~100℃에서 물, 탄소수 1~4의 유기용매 또는 이들의 혼합용매로 추출하여 얻은 것임이 바람직하다. 이때 돌콩과 바나바잎을 1:3 내지 3:1의 중량비로 혼합하는 것이 바람직하다. When the complex is a mixture of dolomite and barnaby leaves, it is preferable that the complex is obtained by extracting a mixture of dolomite and barnaby leaves with water, an organic solvent having 1 to 4 carbon atoms, or a mixed solvent thereof at 0 to 100 ° C. At this time, it is preferable to mix the barnyard and barna leaves at a weight ratio of 1: 3 to 3: 1.
상기 복합물이 돌콩분말과 바나바잎 추출물의 혼합물일 때, 상기 돌콩분말은 돌콩분말을 건조시킨 건조분말 또는 돌콩분말을 40~100℃로 열처리하여 얻은 열처리된 분말인 것이 바람직하다. 이때 돌콩분말과 바나바잎 추출물을 1:3 내지 3:1의 중량비로 혼합하는 것이 바람직하다. When the complex is a mixture of a spinach powder and a banaba leaf extract, the spinach powder is preferably a heat-treated powder obtained by heat-treating the dried powder or the spinach powder dried at 40 to 100 ° C. At this time, it is preferable to mix the dolchol powder and the barna leaf extract at a weight ratio of 1: 3 to 3: 1.
또한, 본 발명은 돌콩과 바나바잎 복합물을 유효성분으로 함유하는 당뇨병의 예방 및 개선용 식품조성물을 제공한다. 상기 복합물에 대한 설명은 위와 동일하다. In addition, the present invention provides a food composition for prevention and improvement of diabetes mellitus containing as an active ingredient a complex of stigma and banaba leaf. The description of the complex is the same as above.
상기 식품조성물에서, 상기 식품은 정제, 캡슐, 분말, 과립, 액상 및 환 중 어느 하나의 형태를 갖는 것이 바람직하다.In the above food composition, it is preferable that the food has any one of a tablet, a capsule, a powder, a granule, a liquid and a ring.
상기 식품조성물에서, 상기 식품은 음료, 분말음료, 고형물, 츄잉검, 차, 비타민 복합제 및 식품 첨가제 중 어느 하나의 형태를 갖는 것이 바람직하다.In the above food composition, it is preferable that the food has any one of a beverage, a powdered beverage, a solid, a chewing gum, a tea, a vitamin complex, and a food additive.
본 발명의 돌콩과 바나바잎 복합물은 부작용은 없으면서 이들을 각각 사용한 경우에 비해 혈당강하효과 및 고인슐린증 개선효과가 훨씬 증강된다. 상기 복합물을 유효성분으로 하는 본 발명의 조성물은 높은 효과와 낮은 부작용으로 당뇨병 예방, 치료 및 개선을 위한 약학 조성물 및 식품조성물로서 유용하게 이용될 수 있다.The inventive black bean and barnaby leaf composite have significantly improved blood glucose lowering effect and hyperinsulinemia improving effect compared to the case of using them without side effects. The composition of the present invention comprising the complex as an active ingredient can be usefully used as a pharmaceutical composition and a food composition for preventing, treating and improving diabetes by high and low side effects.
도1은 돌콩과 바나바잎 추출물 및 이들 복합물의 혈당감소효과를 확인한 결과이다(*p<0.05, ***p<0.001).
도 2는 돌콩과 바나바잎 추출물 및 이들 복합물의 인슐린감소효과를 확인한 결과이다(*p<0.01, *p<0.05, ***p<0.001). FIG. 1 shows the results of confirming the blood glucose lowering effects of the extracts of Barnacle and Barnaby and their complexes (* p <0.05, *** p <0.001).
FIG. 2 shows the results of insulin reduction effect of the extract of Dolomack and Barnaby Leaf and their combination (* p <0.01, * p <0.05, *** p <0.001).
본 발명의 항당뇨 조성물의 유효성분은 돌콩과 바나바잎으로, 돌콩은 분말상태 또는 추출물로 이용될 수 있으며, 바나바잎은 추출물로 이용될 수 있다. The active ingredient of the anti-diabetic composition of the present invention may be used as a sweet potato and a banaba leaf, and a sweet pot may be used as a powdery state or an extract, and a banaba leaf may be used as an extract.
돌콩(Glycine soja)은 자연상태에서 자생하는 돌콩 및 재배된 돌콩을 모두 사용할 수 있으며, 생두 또는 분말의 형태로 사용할 수 있다. Glycine soja) can be used both for the cultivation and dolkong dolkong that grows in nature, it can be used in the form of green beans or powder.
돌콩분말은 돌콩을 통상적인 건조방법에 따라 건조시킨 후 분쇄기로 갈아서 제조하며, 돌콩분말은 바람직하게는The dolchol powder is prepared by drying the dolch in accordance with a conventional drying method and grinding it with a pulverizer,
상기 복합물은 ‘돌콩분말’과 ‘바나바잎 추출물’의 혼합물로, 상기 돌콩분말은 바람직하게는 돌콩분말을 건조시킨 건조분말 또는 돌콩분말을 40~100℃로 열처리하여 얻은 열처리된 분말이 될 수 있다. 이때 상기 “건조”는 건조 온도나 방법에 제한이 없으며 동결건조, 열풍건조, 상온건조 등을 모두 포함하는 의미이다. The complex may be a mixture of a 'dolch powder' and a 'banaba leaf extract', and the dolch powder may preferably be a heat-treated powder obtained by heat-treating a dried or powdered dolch powder dried at 40 to 100 ° C . Herein, the term " drying " means that the drying temperature and the method are not limited and includes both freeze drying, hot air drying, and room temperature drying.
돌콩 추출물은, 돌콩에 시료 중량의 약 2 내지 15배, 바람직하게는 약 5 내지 10배에 달하는 부피의 용매를 가하고 바람직하게는 100℃ 이하, 보다 바람직하게는 0~100℃에서 추출하여 얻으며, 특히 바람직하게는 0~90℃에서 추출하여 얻는다. 상기 용매로는 물, 탄소수 1~4의 유기용매, 또는 이들의 혼합용매를 사용하는 것이 바람직하며, 물, 탄소수 1~4의 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등) 및 이들의 혼합용매 중에서 선택된 어느 하나의 극성 용매를 사용하는 것이 보다 바람직하다. 추출방법은 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 등 공지의 추출방법을 적용할 수 있다. 특히 바람직하게는 90℃ 이하의 온수로 추출한 후 감압 농축하여 돌콩 추출물을 얻는다. The crude extract is obtained by adding a solvent having a volume of about 2 to 15 times, preferably about 5 to 10 times the weight of the sample to the molasses, preferably at 100 占 폚 or less, more preferably 0 to 100 占 폚, Particularly preferably 0 to 90 캜. As the solvent, it is preferable to use water, an organic solvent having 1 to 4 carbon atoms or a mixed solvent thereof, and water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.) It is more preferable to use any polar solvent selected from among the polar solvents. As the extraction method, known extraction methods such as hot water extraction, cold extraction, reflux cooling extraction, and ultrasonic extraction can be applied. Particularly preferably, it is extracted with hot water at 90 DEG C or lower, and then concentrated under reduced pressure to obtain a malt extract.
바나바잎은 열대나 아열대지방에서 자생하고 있는 다년생 상록수인 바나바 (Lagerstroemmia speciosa Pers.)의 잎으로, 주요성분으로 코로솔산, 아연, 철분, 칼슘, 마그네슘 등이 포함되어 있으며, 코로솔산은 잎마다 차이는 있지만 평균적으로 0.1~0.35% 정도가 들어 있다.Barna leaves are leaves of Lagerstroemmia speciosa Pers., A perennial evergreen tree native to tropical and subtropical regions. Main components are corosolic acid, zinc, iron, calcium, and magnesium. But it is 0.1 ~ 0.35% on average.
바나바잎 추출물도 상기 돌콩 추출물과 동일한 방법으로 얻는다. 즉, 바나바잎에 시료 중량의 약 2~15배, 바람직하게는 약 5~10배에 달하는 부피의 용매를 가하고 바람직하게는 100℃ 이하, 보다 바람직하게는 0~100℃에서 추출하여 얻으며, 특히 바람직하게는 0~90℃에서 추출하여 얻는다. 상기 용매로는 물, 탄소수 1~4의 유기용매, 또는 이들의 혼합용매를 사용하는 것이 바람직하며, 물, 탄소수 1~4의 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등) 및 이들의 혼합용매 중에서 선택된 어느 하나의 극성 용매를 사용하는 것이 보다 바람직하다. 추출방법은 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 등 공지의 추출방법을 적용할 수 있다. 특히 바람직하게는 90℃ 이하의 온수로 추출한 후 감압 농축하여 돌콩 추출물을 얻는다. Leaf extract of Barnabas is also obtained in the same manner as the Dolomoe Extract. Namely, the extract is obtained by adding a solvent having a volume of about 2 to 15 times, preferably about 5 to 10 times the weight of the sample to the leaf of barbara, preferably at 100 占 폚 or less, more preferably at 0 to 100 占 폚, Preferably at 0 to 90 캜. As the solvent, it is preferable to use water, an organic solvent having 1 to 4 carbon atoms or a mixed solvent thereof, and water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.) It is more preferable to use any polar solvent selected from among the polar solvents. As the extraction method, known extraction methods such as hot water extraction, cold extraction, reflux cooling extraction, and ultrasonic extraction can be applied. Particularly preferably, it is extracted with hot water at 90 DEG C or lower, and then concentrated under reduced pressure to obtain a malt extract.
본 발명의 돌콩과 바나바잎 복합물은 돌콩과 바나바잎을 함께 추출하여 제조하거나, 별도로 제조된 돌콩 추출물과 바나바잎 추출물을 혼합하여 제조할 수 있다. 돌콩과 바나바잎은 혼합하여 함께 추출할 때 돌콩과 바나바잎을 3:1 내지 1:3의 중량비로 혼합하는 것이 바람직하며, 1:1의 중량비로 혼합하는 것이 특히 바람직하다. 또, 돌콩 추출물과 바나바잎 추출물을 혼합하여 복합물을 구성할 때 돌콩 추출물과 바나바잎 추출물을 3:1 내지 1:3의 중량비로 혼합하는 것이 바람직하며, 1:1의 중량비로 혼합하는 것이 특히 바람직하다. 이와 같이 일정 비율로 혼합한 복합물을 구성함으로써 각 추출물을 단독으로 사용하거나 시차를 두고 따로 복용하는 경우에 비해 항당뇨효과는 크게 높아지면서도 부작용은 없는 우수한 항당뇨 효과를 얻을 수 있다. The present invention can be produced by extracting a combination of a dolomite and a banaba leaf, or by mixing a separately prepared dolomoe extract and a banaba leaf extract. It is preferable that the molasses and the banaba leaf are mixed at a weight ratio of 3: 1 to 1: 3, and it is particularly preferable to mix the molasses at a weight ratio of 1: 1. In addition, it is preferable to mix the barnyardgrass extract and the barna leaf extract at a weight ratio of 3: 1 to 1: 3, and it is particularly preferable to mix them at a weight ratio of 1: 1 when the dolomoe extract and the baranba leaf extract are mixed to form a composite material Do. By constituting the complex mixture at a certain ratio as described above, it is possible to obtain an excellent anti-diabetic effect with no side effects while the antidiabetic effect is greatly enhanced compared with the case where each extract is used alone or separately at a time difference.
상기 본 발명의 돌콩과 바나바잎 복합물을 함유하는 당뇨병의 예방 및 치료용 약학 조성물은 조성물 총 중량에 대하여 상기 복합물을 0.1~99.9중량% 포함한다. The pharmaceutical composition for prevention and treatment of diabetes containing the above-mentioned dolomite and barna leaf composite according to the present invention comprises 0.1 to 99.9% by weight of the above complex relative to the total weight of the composition.
본 발명의 약학 조성물은 약학 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명의 복합물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 다른 약학적 활성화합물과 함께 사용될 수 있다. The pharmaceutical dosage forms of the combination of the present invention may be used in the form of their pharmaceutically acceptable salts and may also be used alone or in combination with other pharmaceutically active compounds.
본 발명의 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 복합물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 통상적으로 사용되는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 복합물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 젤라틴 등을 혼합하여 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크와 같은 윤활제들도 사용된다. 경구용 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 액체 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌 글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(Witepsol), 마크로골, 트윈(Tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method have. Examples of carriers, excipients and diluents that can be included in the composition including the complex include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant and the like is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the oral liquid preparation include suspensions, solutions, emulsions, and syrups. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Witepsol, macrogol, Tween 61, cacao paper, laurin, glycerogelatin and the like may be used as a base for suppositories.
본 발명의 복합물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르며, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 복합물은 1일 0.0001~10,000mg/kg으로 투여하는 것이 바람직하다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the combination of the present invention will depend on the condition and weight of the patient, the degree of disease, the type of drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, it is preferable that the complex of the present invention is administered at 0.0001 to 10,000 mg / kg per day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 복합물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(Intracerebroventricular) 주사에 의해 투여될 수 있다. The complex of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injection.
상기 본 발명의 돌콩과 바나바잎 복합물을 함유하는 당뇨병의 예방 및 개선용 식품조성물은 조성물 총 중량에 대하여 상기 복합물을 0.1~99.9중량% 포함한다. 상기 식품은 특히 건강기능식품을 포함한다. 본 발명에서 정의되는 "건강기능식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다. 상기 건강기능식품은 정제, 캡슐, 분말, 과립, 액상 및 환 중 어느 하나의 형태를 가질 수 있다. The diabetic food composition for preventing and improving diabetes containing the complex of the present invention of the present invention comprises 0.1 to 99.9% by weight of the above complex based on the total weight of the composition. Such foods particularly include health functional foods. As used herein, the term " health functional food "means food prepared and processed using raw materials or ingredients having useful functions in the human body. The term" functional " And the like, for the purpose of obtaining a beneficial effect for health use such as exercise. The health functional food may be in the form of one of tablet, capsule, powder, granule, liquid and ring.
또한, 본 발명의 식품조성물은 상기 돌콩과 바나바잎 복합물을 혈당 개선, 지질대사 개선 및 당뇨합병증의 예방 및 치료 효과를 목적으로 다양한 식품 또는 음료 등에 첨가한 형태의 식품조성물이 될 수 있으며, 특히 건강보조식품의 형태로 제공될 수 있다. 상기 식품은, 예를 들어, 음료, 분말음료, 고형물, 츄잉검, 차, 비타민 복합제 및 식품 첨가제 중 어느 하나의 형태를 가질 수 있다. In addition, the food composition of the present invention may be a food composition in which the dolomite and barna leaf complex are added to various foods or beverages for the purpose of improving blood sugar, improving lipid metabolism and preventing and treating diabetic complications, May be provided in the form of supplements. The food may take the form of, for example, beverage, powdered drink, solid, chewing gum, tea, vitamin complex and food additive.
본 발명의 식품조성물은 필수 성분으로 상기 돌콩과 바나바잎 복합물을 함유하는 것 외에는 다른 성분에는 특별한 제한이 없으며 통상의 식품이나 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 다양한 성분을 추가로 함유할 수 있다. 천연 탄수화물의 예로는 포도당, 과당 등의 단당류; 말토스, 슈크로스 등의 이당류; 덱스트린, 시클로덱스트린 등의 다당류; 및 자일리톨, 소르비톨, 에리스리톨 등의 당알콜이 있다. 향미제로는 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 1~20g, 바람직하게는 약 5~12g이다.The food composition of the present invention is not particularly limited as long as it contains an essential component such as a combination of the dolomite and the banaba leaf, and further contains various components such as various flavors or natural carbohydrates . Examples of natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose and the like; Polysaccharides such as dextrin and cyclodextrin; And sugar alcohols such as xylitol, sorbitol and erythritol. As the flavoring agent, natural flavoring agents (tau martin, stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharin, aspartame, etc.) It is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 성분외에도 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 시료는 천연 과일 주스 및 과일 주스 음료 및 채소 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하지는 않지만 본 발명의 조성물 전체 중량 중 0~20 중량%의 범위에서 선택되는 것이 일반적이다.In addition to the above components, the composition of the present invention may further contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, A salt thereof, an organic acid, a protective colloid thickener, a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, and the like. In addition, the samples of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0 to 20 wt% of the total weight of the composition of the present invention.
이하 본 발명을 실시예를 통해 자세히 설명한다. 단, 하기 실시예 및 실험예는 본 발명을 예시하는 것으로서 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of examples. However, the following examples and experimental examples illustrate the present invention, and the content of the present invention is not limited by the following examples and experimental examples.
[실시예][Example]
<실시예 1> ≪ Example 1 >
돌콩 물추출물의 제조Manufacture of Dolomite Water Extract
돌콩 1kg에 물 10ℓ를 가하여 85℃에서 5시간 동안 추출하고 이들을 감압 농축하고 건조시켜 돌콩 물추출물(DW) 135g을 얻었다.10 kg of water was added to 1 kg of dolch, and the mixture was extracted at 85 캜 for 5 hours. The mixture was concentrated under reduced pressure and dried to obtain 135 g of a dolchy water extract (DW).
<실시예 2> ≪ Example 2 >
돌콩 에탄올추출물의 제조Preparation of ethanol extract of dolchol
돌콩 1kg에 물 3ℓ와 에탄올 3ℓ를 가하여 80℃에서 4시간 동안 추출하고 이들을 감압 농축하고 건조시켜 돌콩 에탄올추출물(DE) 150g을 얻었다.Three kilograms of water and 3 liters of ethanol were added to 1 kilogram of dolch, and the mixture was extracted at 80 DEG C for 4 hours. The filtrate was concentrated under reduced pressure and dried to obtain 150 g of ethanol extract of dolomite (DE).
<실시예 3> ≪ Example 3 >
돌콩 물추출물과 바나바잎 에탄올추출물의 복합물의 제조Preparation of complex of water extract of dolomoe and ethanol extract of barnaby leaf
바나바잎 에탄올추출물(코로솔산 함량 1%)(BE)과 실시예 1에서 얻어진 돌콩 물추출물(DW)을 1:1로 혼합하여 돌콩 물추출물과 바나바잎 에탄올추출물의 복합물(DWBE)을 얻었다. A mixture (DWBE) of a water extract of barnyardgrass and ethanol extract of Barna leaf was obtained by mixing 1: 1 ethanol extract of barna leaf (corosolic acid content 1%) (BE) and the dolomoe water extract (DW) obtained in Example 1.
<실시예 4><Example 4>
돌콩 에탄올추출물과 바나바잎 에탄올추출물의 복합물의 제조Preparation of a complex of ethanol extract of dolomite and ethanol extract of banaba leaf
바나바잎 에탄올추출물(코로솔산 함량 1%)(BE)과 실시예 2에서 얻어진 돌콩 에탄올추출물(DE)을 1:1로 혼합하여 돌콩 에탄올추출물과 바나나잎 에탄올추출물의 복합물(DEBE)을 얻었다. (DEBE) was obtained by mixing ethanol extract of barna leaves (1% corosolic acid) (BE) and ethanol extract of dolomoe (DE) obtained in Example 2 in a ratio of 1: 1.
[실험예][Experimental Example]
실험동물의 분류 및 처리Classification and treatment of laboratory animals
제2형 당뇨병이 유발된 실험쥐인 6주령의 수컷 C57BLKS/J-db/db 마우스 80마리와 동일한 계통의 정상쥐인 C57BL/6CrSlc 마우스 20마리를 일본 시즈오카 실험센터(Japan Shizuoka Laboratory Center, Shizuoka, Japan)에서 구입하여 온도 20±2℃, 습도 55±5% 및 12시간 낮과 밤의 조건에서 1주일간 적응시켰으며 표준사료(Shizuoka Laboratory Center Inc, Japan)와 식수를 자유롭게 섭취시켰다. Six male C57BLKS / J-db / db mice at 6 weeks of age, who were induced with type 2 diabetes, and 20 normal mice C57BL / 6CrSlc mice of the same lineage were transferred to Japan Shizuoka Laboratory Center, Shizuoka Laboratory, (Shizuoka Laboratory Center Inc, Japan) and water were freely consumed at a temperature of 20 ± 2 ° C, humidity of 55 ± 5% and 12 hours of day and night for 1 week.
실험동물들은 유사한 무게(23.3±0.7g)를 기준으로 하기 표 1과 같이 6군으로 분류하고 각 실험군당 10마리씩 배치하였다.Experimental animals were divided into 6 groups according to similar weight (23.3 ± 0.7 g) as shown in Table 1 below, and 10 animals were placed in each experimental group.
당뇨대조군(Control)은 생리식염수를 투여하였고, 시험군에는 각 조건의 추출물을 4주 동안 매일 경구 투여하였다.Control was administered with physiological saline, and the extracts of each condition were orally administered to the test group daily for 4 weeks.
<실험예 1><Experimental Example 1>
혈당감소효과 확인Confirming blood glucose reduction effect
4주 후 마우스의 흉부를 절개하여 심장에서 혈액을 채취하였다. 채취한 혈액은 즉시 4℃에서 4,000rpm으로 10분간 원심분리하여 혈청을 분리한 후 혈당의 수치를 혈액자동분석기를 이용하여 측정하였고, 측정된 혈당수치를 도 1에 나타내었다. 도 1의 그래프에서 수치는 평균±SEM으로 표시하고 서로 상이한 표시를 갖는 수치는 개개 특정시간의 시점에서 서로 상이하며, 통계학적으로 T 시험법에 의하여 음성 대조군과 비교하여 통계학적으로 유의하다(*p<0.05, ***p<0.001).After 4 weeks, the chest of the mouse was opened and blood was collected from the heart. The collected blood was immediately centrifuged at 4,000 rpm at 4,000 rpm for 10 minutes to separate the serum, and the blood glucose level was measured using an automatic blood analyzer. The measured blood glucose level is shown in FIG. In the graph of FIG. 1, the values are expressed as mean ± SEM, and the values having different indications are different from each other at the time of each specific time, statistically significant compared with the negative control by the T test method (* p < 0.05, *** p < 0.001).
도 1의 결과에서, 당뇨대조군(Control)의 수치는 실험기간이 경과할수록 계속 증가하여 실험 4주에는 510mg/㎗ 이상의 고혈당증을 나타내었다. 반면 돌콩 물추출물(DW100). 돌콩 에탄올추출물(DE100), 바나바잎 에탄올추출물(BE100) 및 복합물들(DWBE200, DEBE100)을 투여한 군의 혈당수치는 모두 낮게 나타났다. In the results of FIG. 1, the value of the control group (control) continued to increase with the lapse of the experiment period, and the hyperglycemia was more than 510 mg / dl at the 4th week of the experiment. While Dolicho Water Extract (DW100). Blood glucose levels in the group treated with the ethanol extract of dolomoe (DE100), ethanol extract of barna leaf (BE100) and the complexes (DWBE200, DEBE100) were all low.
동일한 용량인 100mg/kg/day에서 비교할 때, 돌콩 물추출물과 바나바잎 에탄올추출물의 복합물을 투여한 군(DWBE100)의 혈당수치는 돌콩 물추출물을 투여한 군(DW100)에 비해 약 140mg/㎗ 이상 감소하고, 바나바잎 에탄올추출물을 투여한 군(BE100)에 비해 약 200mg/㎗ 이상 감소하여 돌콩과 바나바잎의 복합에 의한 상승효과로 인하여 혈당의 개선효과가 현저하게 증가되었음을 알 수 있다. Compared to the same dose of 100 mg / kg / day, the blood glucose level of the compound (DWBE100) administered with the combination of the water extract of Dolomoe and the extract of ethanol extract of Barnaby leaf was about 140 mg / dl And decreased by about 200 mg / dl or more in comparison with the group administered with ethanol extract of barnaby leaf (BE100). As a result, the improvement effect of blood glucose was remarkably increased due to the synergistic effect of the combination of the barley and barna leaves.
또한 돌콩 에탄올추출물과 바나바잎 에탄올추출물의 복합물을 투여한 군(DEBE100)의 혈당수치는 돌콩 에탄올추출물을 투여한 군(DE100)에 비해 약 110mg/㎗ 이상 감소하고, 바나바잎 에탄올추출물을 투여한 군(BE100)에 비해 약 170mg/㎗ 이상 감소하여 돌콩과 바나바잎의 복합에 의한 상승효과로 인하여 혈당의 개선효과가 현저하게 증가되었음을 알 수 있다. In addition, the blood glucose level of DEBE100 group treated with a combination of ethanol extract of Dolomoe ethanol and Barnaby leaf was decreased by about 110 mg / dl or more compared with the group treated with ethanol extract of dolomoe ethanol (DE100) (BE100), the improvement effect of the blood glucose was remarkably increased due to the synergistic effect of the combination of the barley and the barna leaves.
<실험예 2> <Experimental Example 2>
인슐린감소효과 확인Check insulin reduction effect
4주 후 마우스의 흉부를 절개하여 심장에서 혈액을 채취하였다. 채취한 혈액은 즉시 4℃에서 4,000rpm으로 10분간 원심분리하여 혈청을 분리한 후 인슐린의 수치를 혈액자동분석기를 이용하여 측정하였고, 측정된 인슐린 수치를 도 2에 나타내었다. 도 2의 그래프에서 수치는 평균±SEM으로 표시하고 서로 상이한 표시를 갖는 수치는 개개 특정시간 시점에서 서로 상이하며, 통계학적으로 T 시험법에 의하여 음성 대조군과 비교하여 통계학적으로 유의하다(*p<0.01, *p<0.05, ***p<0.001).After 4 weeks, the chest of the mouse was opened and blood was collected from the heart. The collected blood was immediately centrifuged at 4,000 rpm at 4,000 rpm for 10 minutes to separate the serum, and the insulin level was measured using an automatic blood analyzer. The measured insulin level is shown in Fig. In the graph of FIG. 2, the values are expressed as mean ± SEM, and the values having different indications are different from each other at specific time points and statistically significant compared with the negative control by the T test method (* p <0.01, * p <0.05, *** p <0.001).
도 2에서 알 수 있는 바와 같이, 당뇨대조군(Control)의 인슐린 수치는 실험 1주부터 정상대조군의 6배 이상으로 증가하여 10.8ng/㎗로서 고 인슐린증을 나타내었다. 반면 실험 4주에 돌콩 추출물, 바나바잎 추출물 및 이들의 복합물을 투여한 군에서의 인슐린 수치는 당뇨대조군에 비하여 최소 3ng/㎖ 이상 낮았다. As can be seen from FIG. 2, the insulin level of the control group (control) increased from 6 to 6 times higher than that of the normal control group at 1 week, indicating 10.8 ng / dl of hyperinsulinemia. On the other hand, the insulin levels in the group treated with the extract of Dolomoe extract, Barnaby leaf extract and the complex thereof at 4 weeks were lower than that of the diabetic control by at least 3 ng / ㎖.
혈당 수치와 마찬가지로 동일한 용량인 100mg/kg/day에서 돌콩 물추출물과 바나바잎 에탄올추출물의 복합물을 투여한 군(DWBE100)의 인슐린수치는 돌콩 물추출물을 투여한 군(DW100)에 비해 약 2.8ng/㎗ 이상 감소하고, 바나바잎 에탄올추출물을 투여한 군(BE100)에 비해 약 3.5ng/㎗ 이상 감소하여, 돌콩과 바나바잎의 복합에 의한 상승효과로 인하여 인슐린증을 개선시키는 효과가 현저하게 증가하였음을 알 수 있다. The insulin levels of DWBE100 (100 mg / kg / day), which is similar to the blood glucose level, in the combination of water extract of Dolomoe and ethanol extract of Barna leaves were about 2.8 ng / Dl and decreased more than about 3.5 ng / dl in comparison with the group administered with ethanol extract of barnaby leaf (BE100), and the effect of improving the insulin sensitivity was remarkably increased due to the synergistic effect of the combination of the barley and barna leaves .
또한 돌콩 에탄올추출물과 바나바잎 에탄올추출물의 복합물을 투여한 군(DEBE100)의 인슐린 수치도 돌콩 에탄올추출물을 투여한 군(DE100)에 비해 약 3.1ng/㎗ 이상 감소하고, 바나바잎 에탄올추출물을 투여한 군(BE100)에 비해 약 4.3ng/㎗ 이상 감소하여 돌콩과 바나바잎의 복합에 의한 상승효과로 인하여 인슐린증을 개선시키는 효과가 현저하게 증가하였음을 알 수 있다.In addition, the insulin level of DEBE100 group treated with a combination of ethanol extract of dolomite and barna leaves was decreased by about 3.1 ng / dl more than that of the group treated with ethanol extract of dolomite (DE100), and ethanol extract of banaba leaf (BE100), the effect of improving the insulin sensitivity was remarkably increased due to the synergistic effect of the combination of the barley and barna leaves.
<제조예><Production Example>
본 발명의 복합물을 포함하는 약학 조성물의 제제예를 설명한다. 그러나 하기 제제예는 본 발명을 설명하기 위한 것으로서 본 발명의 범위가 이에 한정되는 것은 아니다.Formulation examples of pharmaceutical compositions comprising the complex of the present invention will be described. However, the following formulation examples are provided for illustrating the present invention, and the scope of the present invention is not limited thereto.
제제예 1. 산제의 제조Preparation Example 1. Preparation of powder
복합물 20mgComplex 20 mg
유당
100mg
탈크 10mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above components are mixed and filled in airtight bags to prepare powders.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
복합물 10mgComplex 10 mg
옥수수전분
100mg
유당
100mg
스테아린산 마그네슘 2mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예 3. 캡슐제의 제조Formulation Example 3. Preparation of capsules
복합물 10mgComplex 10 mg
결정성 셀룰로오스 3mgCrystalline cellulose 3 mg
락토오스 14.8mgLactose 14.8 mg
마그네슘 스테아레이트 0.2mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
복합물 10mgComplex 10 mg
만니톨 180mgMannitol 180 mg
주사용 멸균 증류수 2974mgSterile sterilized water for injection 2974 mg
Na2HPO412H2O 26mgNa 2 HPO 4 12 H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1앰플당(2㎖) 상기의 성분 함량으로 제조한다.(2 ml) per 1 ampoule according to the usual injection preparation method.
Claims (14)
상기 복합물은 돌콩 추출물과 바나바잎 추출물의 혼합물; 돌콩분말과 바나바잎 추출물의 혼합물; 돌콩과 바나바잎의 혼합추출물 중 어느 하나 이상인 것을 특징으로 하는 약학 조성물.The method according to claim 1,
The complex may be a mixture of Dolomoe extract and Barnaby leaf extract; A mixture of dolchol powder and barnaby leaf extract; Wherein the extract is at least one selected from the group consisting of marigold and banaba leaf.
상기 복합물은 돌콩과 바나바잎을 각각 0~100℃에서 물, 탄소수 1~4의 유기용매 또는 이들의 혼합용매로 추출하여 얻은 돌콩 추출물과 바나바잎 추출물을 일정 비율로 혼합한 것임을 특징으로 하는 약학 조성물.3. The method of claim 2,
Wherein the complex comprises a mixture of a mixture of a barnyard extract and a barna leaf extract obtained by extracting a marigold and a banaba leaf with water, an organic solvent having a carbon number of 1 to 4, or a mixed solvent thereof at 0 to 100 ° C. .
상기 복합물은 돌콩과 바나바잎의 혼합물을 0~100℃에서 물, 탄소수 1~4의 유기용매 또는 이들의 혼합용매로 추출하여 얻은 것임을 특징으로 하는 약학 조성물.3. The method of claim 2,
Wherein the complex is obtained by extracting a mixture of a marigold and a banaba leaf with water, an organic solvent having 1 to 4 carbon atoms, or a mixed solvent thereof at 0 to 100 ° C.
상기 복합물은 돌콩분말과 바나바잎 추출물의 혼합물로, 상기 돌콩분말은 돌콩분말을 건조시킨 건조분말 또는 돌콩분말을 40~100℃로 열처리하여 얻은 열처리된 분말인 것을 특징으로 하는 약학 조성물.3. The method of claim 2,
Wherein the complex is a mixture of a spinach powder and a banaba leaf extract, and the spinach powder is a heat-treated powder obtained by heat-treating a dried powder or a spinach powder dried at a temperature of 40 to 100 캜.
상기 복합물은 ‘돌콩추출물, 돌콩분말, 돌콩 중 어느 하나 이상’과 ‘바나바잎, 바나바잎 추출물 중 어느 하나 이상’을 1:3 내지 3:1의 중량비로 혼합하여 얻은 것임을 특징으로 하는 약학 조성물.6. The method according to any one of claims 1 to 5,
Wherein the complex is obtained by mixing at least one selected from the group consisting of at least one of a dolomoe extract, a dolomoe powder, and a dolomite, and at least one of a banana leaf and a banaba leaf extract in a weight ratio of 1: 3 to 3: 1.
상기 복합물은 돌콩 추출물과 바나바잎 추출물의 혼합물; 돌콩분말과 바나바잎 추출물의 혼합물; 돌콩과 바나바잎의 혼합추출물 중 어느 하나 이상인 것을 특징으로 하는 식품조성물.8. The method of claim 7,
The complex may be a mixture of Dolomoe extract and Barnaby leaf extract; A mixture of dolchol powder and barnaby leaf extract; Wherein the composition is at least one selected from the group consisting of a sweet potato and a banaba leaf mixture.
상기 복합물은 돌콩과 바나바잎을 각각 0~100℃에서 물, 탄소수 1~4의 유기용매 또는 이들의 혼합용매로 추출하여 얻은 돌콩 추출물과 바나바잎 추출물을 일정 비율로 혼합한 것임을 특징으로 하는 식품조성물.9. The method of claim 8,
Wherein the complex is a mixture of a barnyard extract and a barna leaf extract which are obtained by extracting from a mixture of water and an organic solvent having a carbon number of 1 to 4 or a mixed solvent thereof at a temperature ranging from 0 to 100 ° C. .
상기 복합물은 돌콩과 바나바잎의 혼합물을 0~100℃에서 물, 탄소수 1~4의 유기용매 또는 이들의 혼합용매로 추출하여 얻은 것임을 특징으로 하는 식품조성물.9. The method of claim 8,
Wherein the complex is obtained by extracting a mixture of a barnyard and a banaba leaf with water, an organic solvent having 1 to 4 carbon atoms, or a mixed solvent thereof at 0 to 100 ° C.
상기 복합물은 돌콩분말과 바나바잎 추출물의 혼합물로, 상기 돌콩 분말은 돌콩분말을 건조시킨 건조된 분말 또는 돌콩분말을 40~100℃로 열처리하여 얻은 열처리된 분말인 것을 특징으로 하는 식품조성물.9. The method of claim 8,
Wherein the complex is a mixture of a spinach powder and a banaba leaf extract, and the spinach powder is a heat-treated powder obtained by heat-treating the dried powder or the spinach powder obtained by drying the spinach powder at 40 to 100 ° C.
상기 복합물은 ‘돌콩추출물, 돌콩분말, 돌콩 중 어느 하나 이상’과 ‘바나바잎, 바나바잎 추출물 중 어느 하나 이상’을 1:3 내지 3:1의 중량비로 혼합하여 얻은 것임을 특징으로 하는 식품조성물.12. The method according to any one of claims 7 to 11,
Wherein the complex is obtained by mixing at least one selected from the group consisting of at least one of a dolomoe extract, a dolomoe powder, and a dolomite, and at least one of a banaba leaf and a banaba leaf extract in a weight ratio of 1: 3 to 3: 1.
상기 식품은 정제, 캡슐, 분말, 과립, 액상 및 환 중 어느 하나의 형태를 갖는 것을 특징으로 하는 식품조성물.12. The method according to any one of claims 7 to 11,
Wherein the food is in the form of any one of tablets, capsules, powders, granules, liquids and rings.
상기 식품은 음료, 분말음료, 고형물, 츄잉검, 차, 비타민 복합제 및 식품 첨가제 중 어느 하나의 형태를 갖는 것을 특징으로 하는 식품조성물.
12. The method according to any one of claims 7 to 11,
Wherein the food has the form of any one of a beverage, a powdered beverage, a solid, a chewing gum, a tea, a vitamin complex, and a food additive.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150126903A KR102460344B1 (en) | 2015-09-08 | 2015-09-08 | Antidiabetic composition comprising complex of wild soya bean and banaba leaves |
| PCT/KR2016/008960 WO2017043776A1 (en) | 2015-09-08 | 2016-08-16 | Antidiabetic composition comprising complex of glycine soja and banaba leaves |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150126903A KR102460344B1 (en) | 2015-09-08 | 2015-09-08 | Antidiabetic composition comprising complex of wild soya bean and banaba leaves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170029828A true KR20170029828A (en) | 2017-03-16 |
| KR102460344B1 KR102460344B1 (en) | 2022-10-31 |
Family
ID=58240058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150126903A KR102460344B1 (en) | 2015-09-08 | 2015-09-08 | Antidiabetic composition comprising complex of wild soya bean and banaba leaves |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102460344B1 (en) |
| WO (1) | WO2017043776A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060107183A (en) | 2005-04-08 | 2006-10-13 | 영농조합법인 영산식품 | A composition comprising the powder or the extract of rhynchosia nulubilis or rhynchosia nulubilis by soaked in vinegar for the prevention and treatment of diabetes mellitus |
| KR20090004503A (en) | 2007-06-29 | 2009-01-12 | 산요덴키가부시키가이샤 | Sealed battery and method of manufacturing the same |
| EP2172206A1 (en) | 2007-05-30 | 2010-04-07 | Lianchuangsiyuanli Biology And Science And Technology Co. Ltd. | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof |
| KR20100127728A (en) | 2009-05-26 | 2010-12-06 | (주)아모레퍼시픽 | Compositions comprising bean extracts for improving blood circulation and vascular health |
| KR20120115471A (en) * | 2011-04-08 | 2012-10-18 | 주식회사 케이오씨바이오텍 | A composition comprising boiled powder or extract of glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005502666A (en) * | 2001-08-31 | 2005-01-27 | オハイオ ユニバーシティー | Compositions and methods for treating a subject having hyperglycemia |
| KR100899712B1 (en) * | 2008-11-04 | 2009-05-28 | 주식회사 일신웰스 | Antioxidant composition comprising fermented banaba extract |
-
2015
- 2015-09-08 KR KR1020150126903A patent/KR102460344B1/en active IP Right Grant
-
2016
- 2016-08-16 WO PCT/KR2016/008960 patent/WO2017043776A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060107183A (en) | 2005-04-08 | 2006-10-13 | 영농조합법인 영산식품 | A composition comprising the powder or the extract of rhynchosia nulubilis or rhynchosia nulubilis by soaked in vinegar for the prevention and treatment of diabetes mellitus |
| EP2172206A1 (en) | 2007-05-30 | 2010-04-07 | Lianchuangsiyuanli Biology And Science And Technology Co. Ltd. | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof |
| KR20090004503A (en) | 2007-06-29 | 2009-01-12 | 산요덴키가부시키가이샤 | Sealed battery and method of manufacturing the same |
| KR20100127728A (en) | 2009-05-26 | 2010-12-06 | (주)아모레퍼시픽 | Compositions comprising bean extracts for improving blood circulation and vascular health |
| KR20120115471A (en) * | 2011-04-08 | 2012-10-18 | 주식회사 케이오씨바이오텍 | A composition comprising boiled powder or extract of glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication |
| KR101400368B1 (en) | 2011-04-08 | 2014-06-19 | 주식회사 케이오씨바이오텍 | A composition comprising boiled powder or extract of Glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017043776A1 (en) | 2017-03-16 |
| KR102460344B1 (en) | 2022-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101976941B1 (en) | Composition comprising an extract of Elaeagnus umbellata for preventing and treating diabetes mellitus | |
| KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
| KR101261029B1 (en) | Composition for preventing or improving the diabete containing suaeda japonica | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR101400368B1 (en) | A composition comprising boiled powder or extract of Glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
| KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| KR102292059B1 (en) | Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes | |
| KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
| KR101808808B1 (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils. | |
| KR102624358B1 (en) | A composition comprising fermented Glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
| KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
| KR101399398B1 (en) | Method for manufacturing submerged-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis | |
| KR101134781B1 (en) | Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus | |
| KR102460344B1 (en) | Antidiabetic composition comprising complex of wild soya bean and banaba leaves | |
| KR101811227B1 (en) | Composition for Immune Enhancement, Fatigue Recovery, Physiologically Active, Detoxification Comprising Extracts of Lycium chinence miller, Rubus coreanus Miq. & Schisandra chinensis | |
| KR20140064067A (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of zanthoxylum piperitum and piper nigrum | |
| KR102474858B1 (en) | Composition for anti-diabetes comprising a mixture of grains | |
| KR101226881B1 (en) | A composition comprising the extract of Proso millet as an active ingredient for preventing and treating inflammatory disease | |
| KR102292060B1 (en) | Composition comprising of the combined extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating obesity | |
| KR101222779B1 (en) | A composition comprising the extract of Barnyardgrass as an active ingredient for preventing and treating inflammatory disease | |
| KR102172371B1 (en) | A pharmaceutical composition comprising extract of Aloe, quince and corn silk for preventing or treating obesity | |
| KR102233672B1 (en) | A composition for improving, preventing and treating of diabetes mellitus comprising Milk thistle and Helianthus tuberosus | |
| KR20130099467A (en) | Food composition for preventing or improving diabetes contaning extract of lespedeza daurica | |
| KR101026857B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
| KR20220117584A (en) | A composition for preventing or improving diabetes containing a radish extract as an active ingredient and a method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |